Turn Therapeutics

Historical price data

Turn Therapeutics is pioneering a new category of precision therapeutics that combine biologic-level efficacy with localized delivery, beginning in dermatologic inflammation. The company's core strategy is to develop topical treatments that act precisely where disease occurs, avoiding the systemic side effects associated with injectable biologics. In addition to its clinical pipeline, Turn has a capital-efficient business model that includes strategic partnerships generating non-dilutive revenue and commercial sales from FDA-cleared wound care products. The company is advancing late-stage clinical programs in eczema and onychomycosis while pursuing global health initiatives in thermostable vaccine delivery.

Patented PermaFusion® drug delivery system enabling localized cytokine modulation through topical administration, designed to deliver biologic-level efficacy without systemic exposure.

1 drug in pipeline

Competes against systemic injectable biologics (Dupixent, Adbry, Rinvoq) in eczema and established wound care products. Differentiation through localized cytokine modulation without systemic exposure, first-in-class mechanism targeting IL-36 pathway, and capital-efficient business model combining commercial revenue with clinical development.